Breast cancer detection research is expanding into Florida communities through a partnership between Mammogen and imaging provider MammoLink. Announced on October 27, 2026, the agreement brings Mammogen’s KATELYN-ERIN trial into MammoLink’s mobile 3D mammography network.

Key Takeaways

  • The prospective trial will evaluate Mammogen’s blood-based RNA assay in approximately 2,600 women.
  • MammoLink operates six mobile 3D mammography units across Florida.

Breast cancer detection study design

The KATELYN-ERIN trial will assess the performance of Mammogen’s genTRU-breast assay against biopsy-confirmed pathology within the breast care pathway. The assay is being developed to complement imaging, rather than replace it.

Mammogen says the test showed strong Stage I breast cancer detection performance in earlier clinical studies. The prospective trial is intended to evaluate its performance in a real-world care setting; the partnership announcement did not provide results from that trial.

How the partnership will reach patients

MammoLink’s Florida network is designed to bring breast imaging closer to women in their communities. The company also offers fixed-site services, including screening and diagnostic mammography and breast ultrasound.

Mammogen CEO Elizabeth Cormier-May said the assay examines RNA signals from both a tumor and the body’s response to disease. The companies hope biological information could eventually complement imaging, including for women with dense breasts, where cancers can be harder to see on mammograms.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.